公开(公告)号：US20230165875A1

公开(公告)日：2023-06-01

申请号：US17997758

申请日：2021-04-30

Applicant: WisTa Laboratories Ltd.

Inventor： Claude Michel Wischik ,  Mohammad Arastoo ,  Michael Philip Mazanetz

IPC: A61K31/54 ,  A61K45/06 ,  A61K47/02

CPC classification number: A61K31/54 ,  A61K45/06 ,  A61K47/02

Abstract: The present invention provides methods of treating COVID-19 in a subject using methylthioninium compounds.

公开(公告)号：US20230031369A1

公开(公告)日：2023-02-02

申请号：US17620949

申请日：2020-06-30

Applicant: WisTa Laboratories Ltd.

Inventor： Gernot Riedel ,  Valeria Melis ,  Charles Robert Harrington ,  Jochen Klein ,  Grazyna Niewiadomska ,  Marta Steczkowska ,  Karima Schwab ,  Claude Michel Wischil

IPC: A61K31/5415 ,  A61P25/28 ,  A61K45/06

Abstract: The present invention relates generally to methods of treatment of Alzheimer's Disease or Mild Cognitive Impairment which are adapted to avoid negative interactions between combinations of therapeutics. In particular there are disclosed such methods of treatment in which the order of therapeutics is actively controlled to mitigate homeostatic downregulation prior to administration of active, for example disease modifying, therapeutic agents. In certain embodiments therapy with symptomatic treatments (such as modifiers of the activity of acetylcholine or glutamate neurotransmitters) may subsequently be combined with the disease modifying or other active treatment. The invention also applies the findings in relation to homeostatic downregulation to novel methods of clinical trial design.

公开(公告)号：US20220098161A1

公开(公告)日：2022-03-31

申请号：US17499498

申请日：2021-10-12

Applicant: WisTa Laboratories Ltd

Inventor： Colin Marshall ,  Scott Clunas ,  John Mervyn David Storey ,  James Peter Sinclair ,  Thomas Craven Baddeley ,  Ahtsham Ishaq ,  Michael Simpson ,  Craig Williamson ,  Barry Alan Wood ,  Claude Michel Wischik ,  Charles Robert Harrington ,  Janet Elizabeth Rickard ,  David Horsley ,  Yin Sze Loh ,  Karrar Ahmad Khan ,  Christopher Paul Larch

IPC: C07D279/20 ,  A61K31/5415 ,  A61K9/00 ,  A61P35/00 ,  A61P33/06 ,  A61P33/02 ,  A61P31/12 ,  A61P31/18 ,  A61P31/04 ,  A61P31/14 ,  A61K9/20 ,  A61L2/00

Abstract: Disclosed are compounds of general formula (I): and pharmaceutically acceptable salts thereof, formulations, methods and uses in, for example, the treatment of disease.

公开(公告)号：US20200016165A1

公开(公告)日：2020-01-16

申请号：US16320148

申请日：2017-07-25

Applicant: WisTa Laboratories Ltd.

Inventor： Claude Michel Wischik ,  Bjorn Olaf Schelter ,  Damon Jude Wischik ,  John Mervyn David Storey

IPC: A61K31/5415 ,  A61K45/06 ,  A61P25/28 ,  A23L33/15 ,  A23L33/105 ,  A23L33/12 ,  A23P10/28 ,  A23P10/30 ,  B65D75/36

Abstract: The invention provides novel regimens for treatment of neurodegenerative disorders utilising methylthioninium (MT)-containing compounds. The regimens are based on novel findings in relation to the dosage of MT compounds, and their interaction with symptomatic treatments based on modulation of acetylcholinesterase levels.

公开(公告)号：US10047062B2

公开(公告)日：2018-08-14

申请号：US15674229

申请日：2017-08-10

Applicant: WISTA LABORATORIES LTD.

Inventor： James Peter Sinclair ,  Sarah Louise Nicoll ,  John Mervyn David Storey

IPC: C07D279/18 ,  C07C381/02

Abstract: Methods of synthesizing and purifying certain 3,7-diamino-phenothiazin-5-ium compounds (referred to herein as “diaminophenothiazinium compounds”) including Methythioninium Chloride (MTC) (also known as Methylene Blue) are provided.

公开(公告)号：US09675621B2

公开(公告)日：2017-06-13

申请号：US15185803

申请日：2016-06-17

Applicant: WisTa Laboratories Ltd.

Inventor： Claude Michel Wischik ,  John Mervyn David Storey ,  Colin Marshall ,  James Peter Sinclair ,  Thomas Craven Baddeley

IPC: A61K31/5415 ,  C07D279/18 ,  C07D279/20

CPC classification number: A61K31/5415 ,  C07D279/18 ,  C07D279/20

Abstract: Disclosed are methods of synthesis and/or purification of certain 3,7-diamino-phenothiazin-5-ium compounds (“diaminophenothiazinium compounds”) including Methylthioninium Chloride (MTC) (Methylene Blue), and the resulting high purity characterized by a purity greater than 98%, and very low levels of heavy metals and organic impurities Azure A, B, C and MVB. Also disclosed are methods of treatment of a tauopathy or methemoglobinemia in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of the high-purity diaminophenothiazinium compound.

公开(公告)号：US20230165876A1

公开(公告)日：2023-06-01

申请号：US17922837

申请日：2021-04-30

Applicant: WisTa Laboratories Ltd.

Inventor： Claude Michel Wischik ,  Mohammad Arastoo ,  Michael Philip Mazanetz

IPC: A61K31/5415 ,  A61K31/4706

CPC classification number: A61K31/5415 ,  A61K31/4706

Abstract: T he present invention provides methods of treating COV-ID-19 in a subject using methylthioninium compounds.

公开(公告)号：US20220330594A1

公开(公告)日：2022-10-20

申请号：US17620956

申请日：2020-06-29

Applicant: WisTa Laboratories Ltd.

Inventor： Gernot Riedel ,  Charles Robert Harrington ,  Jochen Klein ,  Karima Schwab ,  Claude Michel Wischik

IPC: A23L33/10 ,  B65D25/34 ,  B65D75/36

Abstract: The present invention relates generally to nootropic compositions comprising Leuco-methylthioninium acid salts and their uses for cognitive enhancement in normal (non-demented) individuals.

公开(公告)号：US11344558B2

公开(公告)日：2022-05-31

申请号：US14929111

申请日：2015-10-30

Applicant: WisTa Laboratories Ltd.

Inventor： Claude Michel Wischik ,  Janet Elizabeth Rickard ,  Charles Robert Harrington ,  David Horsley ,  John Mervyn David Storey ,  Colin Marshall ,  James Peter Sinclair ,  Thomas Craven Baddeley

IPC: A61K31/5415 ,  C07D279/22 ,  C07D279/20 ,  C09B21/00

Abstract: Described are methods of preparing reduced 3,7-diamino-10H-phenothiazine (DAPTZ) compounds of formula: wherein: R1 and R9 are independently selected from: —H; C1-4alkyl; C2-4alkenyl; and halogenated C1-4alkyl; each of R3NA and R3NB is independently selected from: —H; C1-4alkyl; C2-4alkenyl; and halogenated C1-4alkyl; each of R7NA and R7NB is independently selected from: —H; C1-4alkyl; C2-4alkenyl; and halogenated C1-4alkyl; each of HX1 and HX2 is independently a protic acid; and pharmaceutically acceptable salts, solvates, and hydrates thereof. These methods are particularly useful for producing stable reduced forms, and with high purity. The stability and purity are especially relevant for pharmaceutical compositions for the treatment of disease. The compounds are useful for treatment of e.g. tauopathies, such as Alzheimer's disease, and also as prodrugs for the corresponding oxidized thioninium drugs.

公开(公告)号：US20220008431A1

公开(公告)日：2022-01-13

申请号：US17349427

申请日：2021-06-16

Applicant: WisTa Laboratories Ltd.

Inventor： Claude Michel Wischik ,  Bjorn Olaf Schelter ,  Damon Jude Wischik ,  John Mervyn David Storey

IPC: A61K31/5415 ,  A23L33/12 ,  A23L33/105 ,  A23P10/28 ,  A23P10/30 ,  A23L33/15 ,  A61P25/28 ,  A61K45/06 ,  B65D75/36

Abstract: The invention provides novel regimens for treatment of neurodegenerative disorders utilising methylthioninium (MT)-containing compounds. The regimens are based on novel findings in relation to the dosage of MT compounds, and their interaction with symptomatic treatments based on modulation of acetylcholinesterase levels.